SCHOOL OF MEDICINE | HEALTH SCIENCES | HSLS | FIND PEOPLE AT PITT  
Steffi Oesterreich, PhD
Professor
B701 Magee-Women's Research Institute
204 Craft Avenue, Pittsburgh, PA 15213

Email:
oesterreichs@upmc.edu
Phone: 412-641-8555


Education
BS, Humboldt University, Berlin, Germany, 1989.
PhD, Humboldt University, Max-Delbrück Center for Molecular Medicine, Berlin, Germany, 1992.
Postdoctoral Fellow, University of Texas Health Science Center, San Antonio, 1996.


Research Areas
Cancer Pharmacology
Organ Pharmacology
Photo of Steffi Oesterreich, PhD

Molecular mechanism and clinical relevance of endocrine response in breast cancer


The Oesterreich lab includes technicians, graduate students and postdoctoral fellows who are trained in a multi-disciplinary research environment to work in basic, translational, and clinical aspects of breast cancer research. Specifically, our research projects focus on the role of co-regulator proteins in estrogen response in breast cancer. Estrogen mediates its potent mitogenic effects through the estrogen receptor (ER), which has been a successful target for endocrine therapy in breast cancer. Despite the success of such treatment, de novo or acquired resistance remains a major problem. A better understanding of how ER works is critical for the development of more efficient therapies, and better prediction for who should receive which form of endocrine therapy.


Over the last years, many dogmas in hormone response have changed, which has opened many exciting novel research areas. Examples are estrogen-mediated repression of gene transcription, and the role of co-repressors in this process, the close connection between estrogen signaling and epigenetic regulation of gene transcription, and the role of regulatory elements which are located far outside the promoter of the estrogen regulated genes, and which might even be on other chromosomes. We are studying these processes using state-of-the-art molecular and cellular techniques, mouse models, and clinical specimens. The ultimate goal of Dr. Oesterreich's research is to use this knowledge for improved diagnosis and endocrine treatment of breast cancer patients.







Important Publications
Pathiraja TN, PB Shetty, J Jelinek, R He, RJ Hartmaier, A Margossian, SG Hilsenbeck, JP Issa and S Oesterreich.  Progesterone receptor isoform-specific promoter methylation:  Association of PRA methylation with worse outcome in breast cancer patients.  Clin Cancer Res, 2011.
Oesterreich S, AV Lee and NE Davidson.  Is it time to reSET the standard for estrogen receptor testing in breast cancer?  J Clin Oncol 28:4101-4103, 2010.
Pathiraja TN, V Stearns and S Oesterreich.  Epigenetic regulation in estrogen receptor positive breast cancer:  Role in treatment response.  J Mammary Gland Biol Neoplasia 15:35-47, 2010.
Hammerich-Hille S, A Tsimelzon, BA Kaipparettu, C Creighton, S Jiang, JM Polo, A Melnick, R Meyer and S Oesterreich.  SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.  J Biol Chem 285:3608-3616, 2010.
Malik S, J Jiang, J Garee, E Verdin, AV Lee, BW O'Malley, W Zhang, NS Belaguli and S Oesterreich.  Intricate interplay between HDAC7 and FoxA1 in estrogen-mediated repression of RPRM.  Mol Cell Biol 30:399-412, 2010.
Hartmaier RJ, S Tcatchou, AS Richter, J Wang, SE McGuire, TC Skaar, JM Rae, K Hemminki, C Sutter N Ditsch, P Bugert, BH Weber, D Niederacher, N Arnold, R Varon-Mateeva, B Wappenschmidt, RK Schmutzler, A Meindl, CR Bartram, B Burwinkel and S Oesterreich.  Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.  BMC Cancer 14:438, 2009.
Kaipparettu BA, AV Lee, MB Kaipparettu and S Oesterreich.  Novel egg white-based 3D cell culture system.  Biotechniques 45:165-168, 2008.
Dobrzycka KM, K Kang, S Jiang, R Meyer, PH Rao, AV Lee and S Oesterreich.  Disruption of scaffold attachment factor B1 leads to TBX2 up-regulation, lack of p19ARF induction, lack of senescence, and cell immortalization.  Cancer Res 66:7859-7863, 2006.




Back to Top